BRIEF-XBiotech Says FDA Approves Xbiotech's IND In Rheumatology
* FDA APPROVES XBIOTECH'S IND IN RHEUMATOLOGY
* XBIOTECH INC (XBIT) - WILL FIRST LAUNCH NATRUNIX IN A PHASE I STUDY TO EVALUATE DOSING FOR SUBCUTANEOUS INJECTIONS
* XBIOTECH INC (XBIT) - ONCE PRELIMINARY DOSING HAS BEEN ESTABLISHED, COMPANY PLANS TO PROCEED WITH PHASE II STUDIES IN RA Source text for Eikon: Further company coverage: